Guardant Health (NASDAQ:GH) Given New $68.00 Price Target at Evercore ISI

Guardant Health (NASDAQ:GH) had its target price upped by Evercore ISI from $60.00 to $68.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

Other research analysts have also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a research note on Saturday, September 27th. Leerink Partners increased their price target on Guardant Health from $70.00 to $75.00 and gave the company an “outperform” rating in a research note on Thursday, September 25th. Raymond James Financial increased their price target on Guardant Health from $59.00 to $61.00 and gave the company an “outperform” rating in a research note on Thursday, July 31st. Wells Fargo & Company began coverage on Guardant Health in a research report on Monday, September 22nd. They set an “overweight” rating and a $72.00 target price for the company. Finally, TD Cowen raised their target price on Guardant Health from $63.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, September 25th. Twenty-three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $65.86.

Guardant Health Stock Performance

Shares of GH opened at $63.44 on Tuesday. Guardant Health has a 52 week low of $20.14 and a 52 week high of $68.00. The stock has a market capitalization of $7.91 billion, a price-to-earnings ratio of -18.94 and a beta of 1.53. The stock has a fifty day moving average of $58.08 and a 200-day moving average of $49.79.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Wednesday, July 30th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.08. The firm had revenue of $232.09 million during the quarter, compared to the consensus estimate of $211.19 million. During the same quarter in the previous year, the company posted ($0.84) earnings per share. The firm’s revenue was up 31.0% on a year-over-year basis. Guardant Health has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Guardant Health will post -2.9 EPS for the current year.

Insider Transactions at Guardant Health

In other Guardant Health news, Director Medina Manuel Hidalgo sold 2,165 shares of the stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $54.16, for a total transaction of $117,256.40. Following the completion of the sale, the director directly owned 851 shares in the company, valued at approximately $46,090.16. This trade represents a 71.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Helmy Eltoukhy sold 300,000 shares of the stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $59.45, for a total value of $17,835,000.00. Following the sale, the chief executive officer owned 2,123,499 shares of the company’s stock, valued at approximately $126,242,015.55. The trade was a 12.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 302,691 shares of company stock valued at $17,981,965. Company insiders own 6.10% of the company’s stock.

Institutional Trading of Guardant Health

Several large investors have recently made changes to their positions in GH. Rhumbline Advisers grew its stake in shares of Guardant Health by 4.9% in the 1st quarter. Rhumbline Advisers now owns 175,432 shares of the company’s stock valued at $7,473,000 after buying an additional 8,202 shares during the period. Handelsbanken Fonder AB grew its stake in shares of Guardant Health by 13.1% in the 1st quarter. Handelsbanken Fonder AB now owns 32,741 shares of the company’s stock valued at $1,395,000 after buying an additional 3,800 shares during the period. Fifth Third Bancorp acquired a new stake in shares of Guardant Health in the 1st quarter valued at about $279,000. Janney Montgomery Scott LLC acquired a new stake in shares of Guardant Health in the 1st quarter valued at about $232,000. Finally, Canton Hathaway LLC acquired a new stake in shares of Guardant Health in the 1st quarter valued at about $353,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.